112 related articles for article (PubMed ID: 3431518)
41. [Intraindividual dose-response relationship of sustained-release Elantan].
Kenedi P
Z Kardiol; 1986; 75 Suppl 3():77-9. PubMed ID: 3541420
[TBL] [Abstract][Full Text] [Related]
42. Effect of sustained action isosorbide dinitrate on exercise performance in patients with ischemic heart disease.
Brunner D; Meshulam N; Zerieker F
Acta Cardiol; 1974; 29(4):281-93. PubMed ID: 4607749
[No Abstract] [Full Text] [Related]
43. [Use of the exercise test for determining the optimal dose of prolonged-action nitrates in patients with angina pectoris].
Martsevich SIu; Vygodin VA; Metelitsa VI
Ter Arkh; 1981; 53(12):22-6. PubMed ID: 7347239
[No Abstract] [Full Text] [Related]
44. [4 different nitrate preparations with regard to the possible development of tolerance in long-term treatment].
Mertens HM; Ohlmeier H; Mannebach H; Kabelitz K; Gleichmann U
Herz; 1985 Jun; 10(3):172-81. PubMed ID: 3926614
[TBL] [Abstract][Full Text] [Related]
45. [The effect on painful and silent myocardial ischemia of the preparations Efox and Efox Long in patients with stenocardia of effort].
Belousov IuB; Egorova NA; Karasev AV; Upnitskiĭ AA
Ter Arkh; 1997; 69(9):45-7. PubMed ID: 9411825
[TBL] [Abstract][Full Text] [Related]
46. [Comparison of 2 recent isosorbide dinitrate preparations as new long-term galenicals with commonly used delayed-action preparations].
Hagel H
ZFA (Stuttgart); 1984 Jan; 60(1):40-3. PubMed ID: 6711082
[No Abstract] [Full Text] [Related]
47. Mononitrates as monotherapy in the prophylactic treatment of angina pectoris.
Rehnqvist N; Nyberg G; Carlens P; Lindström E; Lundman T; Nordlander R; Ulvenstam G; Aberg A; Aström H
Drugs; 1987; 33 Suppl 4():100-3. PubMed ID: 3622313
[TBL] [Abstract][Full Text] [Related]
48. [Influence of combination therapy (isosorbide dinitrate and molsidomine) on the incidence of angina pectoris in patients with coronary heart disease].
Ciopor M; Fischer A; Turina J; Hess OM
Praxis (Bern 1994); 1997 Nov; 86(47):1849-53. PubMed ID: 9480502
[TBL] [Abstract][Full Text] [Related]
49. [Hemodynamic effects of isosorbide-5-mononitrate in ischemic cardiopathy].
Russo G; Tolaro S; Monaco O; Greco G; Grassi R; Monaco A; Calvi V; Felis S; Tamburino C; Giuffrida G
Cardiologia; 1988 Mar; 33(3):291-5. PubMed ID: 3401892
[No Abstract] [Full Text] [Related]
50. [Effectiveness of the delayed-action form of isosorbide 5-mononitrate in ischemic heart disease].
Hůla J; Trhlíková M
Vnitr Lek; 1991 Mar; 37(3):248-54. PubMed ID: 2031313
[TBL] [Abstract][Full Text] [Related]
51. [Clinical use of slow-release isosorbide-5-mononitrate in cardiac insufficiency].
Caponnetto S; Canale C; Terrachini V; Masperone MA
Cardiologia; 1987 Nov; 32(11):1303-9. PubMed ID: 3447704
[No Abstract] [Full Text] [Related]
52. Intra-individual comparison of the action of equal doses of isosorbide-5-endomononitrate, slow-release isosorbide dinitrate and placebo in patients with coronary heart disease.
Müller G; Häcker W; Schneider B
Klin Wochenschr; 1983 Apr; 61(8):409-16. PubMed ID: 6408299
[No Abstract] [Full Text] [Related]
53. [Comparison of the efficacy and duration of action of 2 isosorbide dinitrate preparations].
Magelli C; Marzocchi A; Ferretti RM; Bassein L; Magnani B
Cardiologia; 1982; 27(6):609-14. PubMed ID: 6892440
[No Abstract] [Full Text] [Related]
54. Isosorbide mononitrate for angina.
Med Lett Drugs Ther; 1992 Jun; 34(873):61. PubMed ID: 1608345
[No Abstract] [Full Text] [Related]
55. [Influence of isosorbide-5-mononitrate on the tolerance test to exertion in angina pectoris].
Cherchi A; Lai C; Onnis E; Cherchi A; Meloni L; Pirisi R
Cardiologia; 1985 Jun; 30(6):439-48. PubMed ID: 3833355
[No Abstract] [Full Text] [Related]
56. Interval treatment of coronary artery disease with sustained-release isosorbide-5-mononitrate.
Jansen W; Prenze R; Kümper H; Tauchert M
Am J Cardiol; 1990 Jun; 65(21):16J-22J. PubMed ID: 2349913
[TBL] [Abstract][Full Text] [Related]
57. [Long-term therapy with nitrates. Relation between dosage and tolerance effect].
Tauchert M; Jansen W; Metternich M; Osterspey A
Herz; 1984 Jun; 9(3):153-65. PubMed ID: 6430769
[TBL] [Abstract][Full Text] [Related]
58. Anti-ischemic and antianginal effects of 60 mg isosorbide-5-mononitrate in patients treated chronically after myocardial infarction.
Wrobel N
Eur J Clin Pharmacol; 1990; 38 Suppl 1():S61-4. PubMed ID: 2354714
[TBL] [Abstract][Full Text] [Related]
59. [Lack of tolerance development in interval therapy with 50 mg isosorbide-5-nitrate retard (Elantan long)].
Jansen W; Prenzel R; Kümper H; Weidmann B; Tauchert M
Z Kardiol; 1989; 78 Suppl 2():72-8; discussion 115-7. PubMed ID: 2511697
[TBL] [Abstract][Full Text] [Related]
60. Comparison of antianginal efficacy of sustained release isosorbide dinitrate with short-acting isosorbide dinitrate.
Joseph G
Indian Heart J; 1991; 43(6):477. PubMed ID: 1823901
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
